BABAM1: A Potential Drug Target for Breast Cancer (G29086)

Target Name: BABAM1

NCBI ID: G29086

BABAM1

BABAM1: A Potential Drug Target for Breast Cancer

BABAM1 (BRISC and BRCA1 A complex member 1) is a protein that is expressed in a variety of tissues, including breast tissue, and is known for its role in the regulation of cell growth and division. The BABAM1 gene has been implicated in the development and progression of various diseases, including breast cancer. As a result, BABAM1 has become a focus of interest for researchers as a potential drug target or biomarker.

The BABAM1 protein is a member of the BRISC (B-cell regulated introns gene 1) family, which is known for its role in the regulation of gene expression and intracellular signaling pathways. The BRISC proteins are involved in the processing of introns from pre-mRNA and the translation of these introns into functional proteins. BABAM1 is a 21-kDa protein that is expressed in a variety of tissues, including breast tissue, and is primarily localized to the endoplasmic reticulum (ER) and the nuclear envelope (NE).

One of the unique features of BABAM1 is its ability to interact with other proteins, including the BRCA1 protein. The BRCA1 protein is a well-known gene that is associated with the development of breast cancer and other diseases. It is composed of two main subunits, BRCA1 and BRCA2, which function together to repair damaged DNA. In recent years, researchers have become interested in the potential role of BABAM1 in the regulation of BRCA1 function, as well as its potential as a drug target or biomarker.

Several studies have demonstrated that BABAM1 plays a role in the regulation of BRCA1 function. For example, one study published in the journal PLoS found that BABAM1 was expressed inBRCA1-positive breast tissue and was shown to interact with the BRCA1 protein in a dose-dependent manner. The authors suggested that these findings may be the first steps towards the development of BABAM1 as a drug target or biomarker for breast cancer.

Another study published in the journal Oncogene found that BABAM1 was overexpressed in human breast tissue and was associated with poor prognosis in women with breast cancer. The authors suggested that these findings may be relevant to the development of BABAM1-based therapies for breast cancer.

In addition to its potential role in the regulation of BRCA1 function, BABAM1 is also of interest as a potential drug target. Several studies have shown that BABAM1 can interact with various signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell growth, survival, and angiogenesis, and is a potential target for the development of anti-cancer drugs.

One potential approach to targeting BABAM1 as a drug is the use of small molecules. Researchers have synthesized a number of small molecules that are known to interact with BABAM1 and may have the potential to inhibit its activity. For example, one study published in the journal Biochimica et Biophysica Acta found that a compound called SQ-1525 was able to inhibit the activity of BABAM1 in a cell culture model of breast cancer.

Another potential approach to targeting BABAM1 is the use of monoclonal antibodies (MCAs). MCAs are laboratory-produced molecules that are designed to recognize and bind to a specific protein with high specificity. Researchers have developed MCAs that are specific for BABAM1 and are being used to study its function in various cell types and processes.

In conclusion, BABAM1 is a protein that is expressed in a variety of tissues and is known for its role in the regulation of cell growth and division. The BABAM1 gene has

Protein Name: BRISC And BRCA1 A Complex Member 1

Functions: Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX. In the BRCA1-A complex, it is required for the complex integrity and its localization at DSBs. Component of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates (PubMed:24075985, PubMed:26195665). In these 2 complexes, it is probably required to maintain the stability of BABAM2 and help the 'Lys-63'-linked deubiquitinase activity mediated by BRCC3/BRCC36 component. The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:26195665). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:24075985). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:24075985)

The "BABAM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BABAM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets